Navigation Links
Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
Date:9/30/2010

Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be s
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical Reestablishes Biodefense Programs
2. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
3. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
4. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
5. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
6. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
7. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
8. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
9. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
10. Millstone Medical Outsourcing Makes Strategic Hires in Memphis
11. Open Door Family Medical Centers Named Top Community Health Center in Nation for Use of Information Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... RA Signs and Symptoms Compared to Placebo, ... (Nasdaq: TRBN ) today announced preliminary ... double-blind, placebo-controlled, multicenter,clinical trial of its TRU-015 ... indicated that Trubion,s TRU-015 product candidate, at,well-tolerated ...
... Calif., Sept. 10 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... antibodies for the treatment of cancer and,hepatitis C ... submitted a,clinical protocol with the Drug Controller General ... safety and efficacy trial of bavituximab in combination,with ...
Cached Medicine Technology:Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 2Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 3Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 4Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 5Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 4
(Date:5/21/2013)... Dr. James C. Wittig, Chief of Orthopedic ... Division of the John Theurer Cancer Center at Hackensack ... one of the top 13 Orthopedic Oncologists in the ... is one of approximately 125 surgeons in America who ... surveying thought leaders in the field of Oncology. Dr. ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... information on the site for patients taking the blood ... drug may be at more risk of death when ... , DrugRisks was created to improve the safety of ... warnings, recalls, studies and legal news. Visitors can see ...
(Date:5/20/2013)... The India Network Foundation, a ... insurance, announces a new pre-existing condition coverage plan: ... the years, India Network members have requested a ... maximums, and duration. The Platinum Comprehensive Plan is ... the valuable coverage and benefits of a PPO ...
(Date:5/20/2013)... Southfield, Michigan (PRWEB) May 21, 2013 This ... National Dog Bite Prevention Week (May 19th-May 25th) is an ... dog bite attacks and by encouraging dog owners to properly ... a dog. , Michigan dog bite lawyers at ... animal attacks in cases throughout Michigan. The personal injury law ...
(Date:5/20/2013)... May 20, 2013 When people ... not always to become a celebrity. New Jersey ... 2013 ABC News report (“Chris Christie Says Lap ... clear that the surgery was not done so ... gain celebrity status as a former lap band ...
Breaking Medicine News(10 mins):Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 3Health News:Buckfire & Buckfire, P.C. Dog Bite Lawyers in Michigan Discuss National Dog Bite Prevention Week 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3
... Feb. 4 The Carol Milgard Breast Center was awarded ... (FDA) for adhering to the most rigorous quality and safety standards ... "All Items in Compliance" rating from the FDA is exceptional because ... high quality standard.   , John Peixotto , M.D., a ...
... American Society for Radiation Oncology (ASTRO) and the ... guidelines for image guided radiation therapy (IGRT) and ... issue of the International Journal of Radiation ... guidelines were released as educational tools to assist ...
... reveals new way to repair damage with natural tissue ... nanofiber gel that promotes cartilage growth in joints has ... injected into the damaged joint and stimulates bone marrow ... for expensive growth factors. No current therapy can do ...
... , ... Foundation and Shands HealthCare announce today that they have ... needs assessment for a Gainesville -based children,s hospital. The assessment began ... , "We are confident that the experts at Sg2 will ...
... , NEW YORK , Feb. 4 ... announced more than $2.8 million in awards for ... PD. The development of biomarkers is of critical importance to ... scientists and clinicians to more accurately identify appropriate subjects for ...
... February 4, 2010 -- Giving smokers information about their ... to quit smoking, according to a paper published in ... "Personalized risk assessment has been the mainstay of ... mortality reduction over the last decade," said Dr. Robert ...
Cached Medicine News:Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:ASTRO, ACR issue IGRT, SBRT guidelines 2Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 2Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 4Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 2Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 3
Anorectal Stylet for LATITUDE® Air-Charged Catheter...
Omnilink Adapter Cable for LATITUDE® Air-Charged Catheter...
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
... The ITREL 3 is a battery ... in the U.S., ,Enterra™ Therapy is ... and vomiting associated with gastroparesis when conventional ... of symptons for diabetic or idiopathic patients., ...
Medicine Products: